Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

Table 3

Results of subgroup analyses for progression-free survival.

Subgroup		HR	95% CI	Test of heterogeneity; -value	Test of heterogeneity; value	coefficient
Age
<65 years	1670	0.62	0.47–0.82			89.21%
≥65 years	1165	0.74	0.66–0.84			0%
Sex
Male	1907	0.68	0.54–0.84			77.40%
Female	1110	0.66	0.49–0.89			80.51%
ECOG status
0	1440	0.61	0.48–0.80			81.64%
≥1	1385	0.73	0.60–0.88			54.09%
KRAS status
Wildtype	1219	0.60	0.47–0.76			76.62%
Mutation	1326	0.66	0.53–0.83			80.67%